Po-Chu Kuo Selected Research

1- (2,4- dichlorophenyl)- N- (piperidin- 1- yl)- 4- ((pyrrolidine- 1- sulfonamido)methyl)- 5- (5- ((4- (trifluoromethyl)phenyl)ethynyl)thiophene- 2- yl)- 1H- pyrazole- 3- carboxamide

12/2013

Discovery of 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a novel peripherally restricted cannabinoid-1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Po-Chu Kuo Research Topics

Disease

4	Neoplasms (Cancer) 01/2020 - 12/2016
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2019 - 07/2015
2	Carcinoma (Carcinomatosis) 05/2018 - 01/2017
1	Leukemia 01/2020
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 12/2019
1	Weight Loss (Weight Reduction) 12/2013
1	Colonic Neoplasms (Colon Cancer) 07/2013

Drug/Important Bio-Agent (IBA)

4	Phosphotransferases (Kinase)IBA 01/2020 - 12/2016
2	QuinazolinesIBA 01/2020 - 12/2016
1	tyrosine receptor (receptor, tyrosine)IBA 12/2019
1	Tyrosine Kinase InhibitorsIBA 12/2019
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2019
1	Proto-Oncogene Proteins c-kit (Proto-Oncogene Protein c-kit)IBA 12/2019
1	Glutamic Acid (Glutamate)FDA Link 01/2017
1	1- (2,4- dichlorophenyl)- N- (piperidin- 1- yl)- 4- ((pyrrolidine- 1- sulfonamido)methyl)- 5- (5- ((4- (trifluoromethyl)phenyl)ethynyl)thiophene- 2- yl)- 1H- pyrazole- 3- carboxamideIBA 12/2013
1	1- (4- (2- ((6- (4- (2- (dimethylamino)ethoxy)phenyl)furo(2,3- d)pyrimidin- 4- yl)amino)ethyl)phenyl)- 3- phenylureaIBA 07/2013
1	Aurora KinasesIBA 07/2013
1	Antineoplastic Agents (Antineoplastics)IBA 07/2013

Therapy/Procedure

3	Therapeutics 01/2020 - 07/2015